HUP0301575A3 - Methods of modifying eukaryotic cells - Google Patents

Methods of modifying eukaryotic cells

Info

Publication number
HUP0301575A3
HUP0301575A3 HU0301575A HUP0301575A HUP0301575A3 HU P0301575 A3 HUP0301575 A3 HU P0301575A3 HU 0301575 A HU0301575 A HU 0301575A HU P0301575 A HUP0301575 A HU P0301575A HU P0301575 A3 HUP0301575 A3 HU P0301575A3
Authority
HU
Hungary
Prior art keywords
methods
eukaryotic cells
modifying eukaryotic
modifying
cells
Prior art date
Application number
HU0301575A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUP0301575A2 publication Critical patent/HUP0301575A2/hu
Publication of HUP0301575A3 publication Critical patent/HUP0301575A3/hu
Publication of HU227639B1 publication Critical patent/HU227639B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HU0301575A 2000-10-31 2001-10-31 Methods of modifying eukaryotic cells HU227639B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24466500P 2000-10-31 2000-10-31
US09/732,234 US6586251B2 (en) 2000-10-31 2000-12-07 Methods of modifying eukaryotic cells
PCT/US2001/045375 WO2002036789A2 (en) 2000-10-31 2001-10-31 Methods of modifying eukaryotic cells

Publications (3)

Publication Number Publication Date
HUP0301575A2 HUP0301575A2 (hu) 2003-09-29
HUP0301575A3 true HUP0301575A3 (en) 2010-01-28
HU227639B1 HU227639B1 (en) 2011-10-28

Family

ID=26936709

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301575A HU227639B1 (en) 2000-10-31 2001-10-31 Methods of modifying eukaryotic cells

Country Status (19)

Country Link
US (1) US6586251B2 (hu)
EP (1) EP1399575B1 (hu)
JP (7) JP5339566B2 (hu)
KR (1) KR100833136B1 (hu)
CN (1) CN100497642C (hu)
AT (1) ATE332388T1 (hu)
AU (2) AU2002220048B2 (hu)
BR (1) BRPI0115096B1 (hu)
CA (1) CA2426398C (hu)
CZ (1) CZ304856B6 (hu)
DE (1) DE60121372T2 (hu)
HK (1) HK1059802A1 (hu)
HU (1) HU227639B1 (hu)
MX (1) MXPA03003797A (hu)
NO (1) NO332300B1 (hu)
NZ (1) NZ525511A (hu)
PL (1) PL204759B1 (hu)
RU (1) RU2290441C2 (hu)
WO (1) WO2002036789A2 (hu)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908744B1 (en) * 2000-03-14 2005-06-21 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
ES2394877T3 (es) * 2000-08-14 2013-02-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinación homóloga mejorada mediada por proteínas de recombinación de lambda
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
JP2006513727A (ja) 2002-05-17 2006-04-27 マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー 中胚葉および成体型内胚葉細胞集団
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
WO2004022738A1 (en) * 2002-09-09 2004-03-18 California Institute Of Technology Methods and compositions for the generation of humanized mice
WO2004067725A2 (en) * 2003-01-30 2004-08-12 Regeneron Pharmaceuticals, Inc. Methods of identifying modulators of nmur2-mediated activity
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2767161B1 (en) 2004-10-19 2018-02-07 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
US20060117396A1 (en) * 2004-11-30 2006-06-01 Murphy Andrew J Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
MX2009010120A (es) 2007-03-22 2009-10-19 Ucb Pharma Sa Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
AU2008259939B2 (en) 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20110119779A1 (en) * 2007-12-10 2011-05-19 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
ES2459880T3 (es) * 2008-04-14 2014-05-12 Sangamo Biosciences, Inc. Construcciones donantes lineales para integración dirigida
US20090328240A1 (en) * 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
DE102008002715A1 (de) * 2008-06-27 2009-12-31 Evonik Röhm Gmbh 2-Hydroxyisobuttersäure produzierende rekombinante Zelle
US9346873B2 (en) 2008-09-30 2016-05-24 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PL2564695T3 (pl) 2009-07-08 2015-10-30 Kymab Ltd Modele zwierzęce i cząsteczki terapeutyczne
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
JP5874881B2 (ja) 2009-10-06 2016-03-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変されたマウスおよび移植方法
TR201903376T4 (tr) 2009-10-29 2019-04-22 Regeneron Pharma Çok fonksiyonlu alleller.
CN110079550A (zh) 2009-12-10 2019-08-02 瑞泽恩制药公司 生产重链抗体的小鼠
CA2784953C (en) 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2603559T5 (es) * 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP4345163A2 (en) 2010-03-31 2024-04-03 Ablexis, LLC Genetic engineering of non-human animals for the production of chimeric antibodies
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
CN113150121A (zh) 2010-08-02 2021-07-23 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
EP2638155A1 (en) 2010-11-08 2013-09-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
MX350385B (es) 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
RS59413B2 (sr) 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
EP2527842B1 (en) 2011-05-12 2013-06-05 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
SI3572517T1 (sl) 2011-08-05 2021-09-30 Regeneron Pharmaceuticals, Inc. Humanizirana miš z univerzalno lahko verigo
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CA2846322A1 (en) 2011-09-19 2013-03-28 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
DK2627773T3 (en) 2011-10-17 2017-10-02 Regeneron Pharma MOUSE WITH LIMITED IMMUNOGLOBULIN HEAVY CHAIN
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
KR102148387B1 (ko) 2011-10-28 2020-08-26 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
HUE035652T2 (hu) 2011-10-28 2018-05-28 Regeneron Pharma Genetikailag módosított fõ hisztokompatibilitási komplexes egerek
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
WO2013066735A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Nano-suspension process
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR102038974B1 (ko) 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
HUE046744T2 (hu) 2012-02-01 2020-03-30 Regeneron Pharma VL doméneket tartalmazó nehézláncokat expresszáló humanizált egér
CN107090471A (zh) 2012-03-06 2017-08-25 瑞泽恩制药公司 共同轻链小鼠
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SG10201607727PA (en) 2012-03-16 2016-11-29 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
SG10201700360VA (en) 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
SG11201405059XA (en) 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
SG11201406547YA (en) 2012-04-25 2014-11-27 Regeneron Pharma Nuclease-mediated targeting with large targeting vectors
HUE047266T2 (hu) 2012-06-12 2020-04-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
AR091482A1 (es) * 2012-06-21 2015-02-04 Recombinetics Inc Celulas modificadas geneticamente y metodos par su obtencion
SG11201501286PA (en) 2012-08-23 2015-05-28 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
KR102312856B1 (ko) 2012-08-24 2021-10-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
UA118090C2 (uk) * 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
JP6283031B2 (ja) 2012-09-07 2018-02-21 イエール ユニバーシティ 遺伝学的に修飾された非ヒト動物およびその使用法
WO2014071397A2 (en) 2012-11-05 2014-05-08 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
SI2840892T1 (en) * 2013-02-20 2018-08-31 Regeneron Pharmaceuticals, Inc. Animals other than humans with modified immunoglobulin heavy chain sequences
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
KR102313047B1 (ko) 2013-02-20 2021-10-19 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
EP2967014B1 (en) 2013-03-11 2019-10-16 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
EP4249507A3 (en) 2013-03-11 2023-12-27 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
AU2014244079A1 (en) 2013-03-13 2015-09-24 Regeneron Pharmaceuticals, Inc. Common light chain mouse
EP3501272B1 (en) 2013-03-13 2023-03-01 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
DK2986729T3 (en) * 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9925273B2 (en) 2013-08-01 2018-03-27 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
DK3178928T3 (da) 2013-08-07 2020-08-24 Regeneron Pharma Pint-knockout-mus med en præmatur, aldersassocieret fænotype
ES2738679T3 (es) 2013-09-18 2020-01-24 Regeneron Pharma Anticuerpos de cadena ligera diseñados genéticamente con histidina y animales no humanos modificados genéticamente para generar los mismos
KR102407354B1 (ko) 2013-09-23 2022-06-10 리제너론 파마슈티칼스 인코포레이티드 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
AU2014353346B2 (en) 2013-11-19 2020-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized B-cell activating factor gene
SG10201811701YA (en) 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
EP3460063B1 (en) 2013-12-11 2024-03-13 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
RU2685914C1 (ru) * 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
WO2015108102A1 (ja) 2014-01-15 2015-07-23 国立大学法人 群馬大学 Ａｔｐ可視化動物およびその用途
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
CA2941514A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
FI3841877T3 (fi) 2014-05-19 2023-12-01 Regeneron Pharma Ihmisen epo:a ilmentäviä geneettisesti muunneltuja hiiriä
MX2016015609A (es) 2014-05-30 2017-08-02 Regeneron Pharma Animales con dipeptidil peptidasa iv (dpp4) humanizada.
KR102374379B1 (ko) 2014-06-06 2022-03-17 리제너론 파마슈티칼스 인코포레이티드 표적화된 좌를 변형시키는 방법 및 조성물
KR102482295B1 (ko) * 2014-06-19 2022-12-30 리제너론 파마슈티칼스 인코포레이티드 인간화 프로그램화 세포 사멸 1 유전자를 가지는 비인간 동물
EP3155099B1 (en) 2014-06-23 2018-03-21 Regeneron Pharmaceuticals, Inc. Nuclease-mediated dna assembly
ES2901074T3 (es) 2014-06-26 2022-03-21 Regeneron Pharma Métodos y composiciones para modificaciones genéticas objetivo y métodos de uso
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
MX2017004890A (es) 2014-10-15 2018-02-12 Regeneron Pharma Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
NZ731962A (en) 2014-11-21 2022-07-01 Regeneron Pharma Methods and compositions for targeted genetic modification using paired guide rnas
CN113016720B (zh) 2014-11-24 2023-02-21 瑞泽恩制药公司 表达人源化cd3复合物的非人类动物
LT3086637T (lt) 2014-12-05 2019-04-10 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuota diferenciacijos klasterio 47 geną
KR102457921B1 (ko) 2014-12-09 2022-10-25 리제너론 파마슈티칼스 인코포레이티드 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물
MX2017008190A (es) 2014-12-19 2018-03-23 Regeneron Pharma Metodos y composiciones para la modificacion genetica dirigida a traves de direccionamiento multiple de una sola etapa.
UA122331C2 (uk) 2015-03-09 2020-10-26 Едженсіс, Інк. Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
EP3270688B1 (en) 2015-03-16 2020-08-12 Regeneron Pharmaceuticals, Inc. Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
NZ736031A (en) 2015-04-06 2022-07-29 Regeneron Pharma Humanized t cell mediated immune responses in non-human animals
PT3282835T (pt) 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
WO2016196185A1 (en) 2015-05-29 2016-12-08 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a c9orf72 locus
WO2017040738A1 (en) 2015-09-02 2017-03-09 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
JP6997708B2 (ja) * 2015-11-20 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
EP3380605A1 (en) * 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transient transfection method for retroviral production
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
EP4257599A3 (en) 2016-01-13 2024-01-17 Regeneron Pharmaceuticals, Inc. Rodents having an engineered heavy chain diversity region
US20170218398A1 (en) * 2016-01-30 2017-08-03 Markus Alexander Brown Method to selectively target cancerous cells for genetic manipulation
KR20180104149A (ko) 2016-02-04 2018-09-19 트리아니, 인코포레이티드 면역글로불린의 증대된 생성
MA43962A (fr) * 2016-02-04 2018-12-12 Regeneron Pharma Animaux non humains possédant un gène angptl8 modifié
US20170247436A1 (en) 2016-02-16 2017-08-31 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
WO2017172958A1 (en) 2016-03-29 2017-10-05 Regeneron Pharmaceuticals, Inc. Genetic variant-phenotype analysis system and methods of use
MX2018014172A (es) 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
AU2017272337C1 (en) 2016-06-03 2024-02-29 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
US10912287B2 (en) 2016-06-28 2021-02-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified mice expressing humanized PD-1
CN109803530A (zh) 2016-07-29 2019-05-24 瑞泽恩制药公司 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
JP7026678B2 (ja) 2016-09-30 2022-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ９ｏｒｆ７２座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物
CN109996441B (zh) 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
KR20190122232A (ko) 2017-02-27 2019-10-29 리제너론 파아마슈티컬스, 인크. 망막층간분리증의 비인간 동물 모델
SG11201912236YA (en) 2017-07-31 2020-01-30 Regeneron Pharma Crispr reporter non-human animals and uses thereof
MX2020001178A (es) 2017-07-31 2020-09-25 Regeneron Pharma Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos.
LT3687287T (lt) 2017-09-29 2023-10-25 Regeneron Pharmaceuticals, Inc. Graužikai, ekspresuojantys humanizuotą c1q kompleksą
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
EP4299732A3 (en) 2017-11-30 2024-03-27 Regeneron Pharmaceuticals, Inc. Rats comprising a humanized trkb locus
CN111432635B (zh) 2017-12-05 2022-10-21 瑞泽恩制药公司 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途
KR20240038811A (ko) 2018-03-19 2024-03-25 리제너론 파마슈티칼스 인코포레이티드 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
CA3101803A1 (en) 2018-06-01 2019-12-05 Regeneron Pharmaceuticals, Inc. Methods and systems for sparse vector-based matrix transformations
US20190380316A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
SG11202011284RA (en) 2018-07-16 2020-12-30 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
CN109504708A (zh) * 2018-12-03 2019-03-22 江苏集萃药康生物科技有限公司 一种筛选标记自我删除的基因打靶载体及方法
EP3732291A1 (en) 2018-12-20 2020-11-04 Regeneron Pharmaceuticals, Inc. Nuclease-mediated repeat expansion
WO2020152607A1 (en) 2019-01-22 2020-07-30 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CA3133360A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
IL286917B (en) 2019-04-04 2022-09-01 Regeneron Pharma Methods for scar-free insertion of targeted modifications into targeted vectors
KR20210153092A (ko) 2019-04-15 2021-12-16 퀴셀 세라퓨틱스 엘엘씨 암 치료에 사용하기 위한, 마스킹된 유형 i 인터페론(ifna 및 ifnb) 및 종양 항원에 대한 항체를 포함하는 융합 단백질 조성물
CN113874510A (zh) 2019-06-04 2021-12-31 瑞泽恩制药公司 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
TW202110323A (zh) 2019-06-05 2021-03-16 美商再生元醫藥公司 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途
KR20220017939A (ko) 2019-06-07 2022-02-14 리제너론 파마슈티칼스 인코포레이티드 인간화 알부민 좌위를 포함하는 비-인간 동물
EP3990475A1 (en) 2019-06-27 2022-05-04 Regeneron Pharmaceuticals, Inc. Modeling tdp-43 proteinopathy
US20220380478A1 (en) 2019-07-01 2022-12-01 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
JP2022550434A (ja) 2019-10-04 2022-12-01 ティーエーイー ライフ サイエンシーズ Ｆｃ変異および部位特異的コンジュゲーション特性を含む抗体組成物
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
CN115175559A (zh) 2020-01-28 2022-10-11 瑞泽恩制药公司 包含人源化pnpla3基因座的非人动物及其使用方法
US20230081547A1 (en) 2020-02-07 2023-03-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
WO2021195079A1 (en) 2020-03-23 2021-09-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
CA3167557A1 (en) 2020-04-21 2021-10-28 Davor Frleta Non-human animals having a humanized cxcl13 gene
RU2751237C1 (ru) * 2020-06-10 2021-07-12 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
CN115988960A (zh) 2020-06-25 2023-04-18 株式会社湖美宝 杂合转基因动物
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
KR20230078677A (ko) 2020-10-01 2023-06-02 리제너론 파마슈티칼스 인코포레이티드 인간 cr1을 발현하는 설치류 동물
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
WO2022140221A1 (en) 2020-12-21 2022-06-30 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene
EP4051700A1 (en) 2020-12-23 2022-09-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
EP4274587A1 (en) 2021-01-06 2023-11-15 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
CA3213460A1 (en) 2021-03-31 2022-10-06 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrb repertoire
EP4324848A1 (en) 2021-04-16 2024-02-21 Korea University Research and Business Foundation Human antibody targeting covid-19 virus
CN117529330A (zh) 2021-06-18 2024-02-06 纳米医疗有限公司 用于治疗癌症的包括所掩蔽的I型干扰素(IFNα和IFNβ)的融合蛋白组合物和其方法
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2023108047A1 (en) 2021-12-08 2023-06-15 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023154861A1 (en) 2022-02-11 2023-08-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
WO2023212560A1 (en) 2022-04-26 2023-11-02 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023235677A1 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
WO2024064860A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
WO2024073679A1 (en) 2022-09-29 2024-04-04 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JPH07509137A (ja) * 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE4228162C1 (de) * 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
US5436149A (en) 1993-02-19 1995-07-25 Barnes; Wayne M. Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension
EP0754225A4 (en) * 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
DK1151010T3 (da) * 1999-02-05 2006-01-09 Therapeutic Human Polyclonals Humane polyklonale antistoffer fra antigene ikke-humane dyr
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells

Also Published As

Publication number Publication date
CZ304856B6 (cs) 2014-12-10
CA2426398C (en) 2010-10-26
WO2002036789A2 (en) 2002-05-10
NZ525511A (en) 2006-02-24
EP1399575B1 (en) 2006-07-05
NO20031897D0 (no) 2003-04-28
JP2004536556A (ja) 2004-12-09
PL361927A1 (en) 2004-10-04
CA2426398A1 (en) 2002-05-10
BRPI0115096B1 (pt) 2016-03-01
KR20030074614A (ko) 2003-09-19
JP5892975B2 (ja) 2016-03-23
JP5945263B2 (ja) 2016-07-05
HU227639B1 (en) 2011-10-28
PL204759B1 (pl) 2010-02-26
JP2015062432A (ja) 2015-04-09
HUP0301575A2 (hu) 2003-09-29
MXPA03003797A (es) 2004-04-20
CN100497642C (zh) 2009-06-10
BR0115096A (pt) 2003-10-07
RU2003116125A (ru) 2005-01-20
US6586251B2 (en) 2003-07-01
JP2017104125A (ja) 2017-06-15
KR100833136B1 (ko) 2008-05-28
RU2290441C2 (ru) 2006-12-27
JP5339566B2 (ja) 2013-11-13
AU2002220048B2 (en) 2006-09-21
CZ20031197A3 (cs) 2003-11-12
JP2013162803A (ja) 2013-08-22
JP2017123855A (ja) 2017-07-20
JP6486979B2 (ja) 2019-03-20
CN1484707A (zh) 2004-03-24
JP2010220628A (ja) 2010-10-07
AU2004802A (en) 2002-05-15
DE60121372D1 (de) 2006-08-17
NO332300B1 (no) 2012-08-20
EP1399575A2 (en) 2004-03-24
ATE332388T1 (de) 2006-07-15
DE60121372T2 (de) 2007-07-26
JP2014039567A (ja) 2014-03-06
HK1059802A1 (en) 2004-07-16
US20020106628A1 (en) 2002-08-08
NO20031897L (no) 2003-06-24
WO2002036789A3 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
HUP0301575A3 (en) Methods of modifying eukaryotic cells
HK1146298A1 (en) Methods of modifying eukaryotic cells
IL154159A0 (en) Directed differentiation of ebryonic cells
IL135466A0 (en) Enzymatic modification of sterols
AU5833701A (en) Improved electrolytic cell
GB2346589B (en) Construction of dies
AU2002216223A1 (en) Preservation of cells
AU4127101A (en) Transformation of eukaryotic cells by mobilizable plasmids
IL155580A0 (en) Methods of modifying eukaryotic cells
ZA200303129B (en) Methods of modifying eukaryotic cells.
GB0118984D0 (en) Fusion of cells
GB0008254D0 (en) Methods of cell killing
TW435832U (en) Improved structure of battery set
AU2001271496A1 (en) Enhanced recovery of transformed cells
TW424905U (en) Improved structure of drum-beater
TW479608U (en) Storage structure improvement of socket
IL147594A0 (en) Methods of inducing cell death
TW452208U (en) Improved structure of battery
TW472516U (en) Improved structure of round spade
TW487243U (en) Structure improvement of charger
TW417710U (en) Modified structure of raised net-flooring
TW432952U (en) Improved structure of lunch-box
TW480914U (en) Improved structure of fishpot
TW458469U (en) Improved structure of earphone
TW474539U (en) Improved structure of multi-sound-channel earphone